Navigation Links
Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference

WEIFANG, Shandong, China, Feb. 3 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has been invited to make a corporate presentation at Roth Capital Partners 21st Annual OC Growth Stock Conference.

This conference will be held from Monday, February 16th through Wednesday, February 18th at The Ritz-Carlton, Laguna Niguel. Details of Shengtai's presentation at the conference are as follows:

     Date: Tuesday, February 17, 2009
     Time: 3:30 - 4:00 P.M. Pacific Standard Time

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc., through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes, and the glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc., please visit .

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

    For more information, please contact:

    Shengtai Pharmaceutical, Inc.
     Ms. Yiru Melody Shi
     Chief Financial Officer
     Tel:   +1-949-468-7078

    Grayling Global
     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical Expands International Sales Program
2. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
4. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
5. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
6. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
7. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
8. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
9. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. West Pharmaceutical Services To Present at the 2009 UBS Global Healthcare Services Conference
Post Your Comments:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: